Department of Cardiac Surgery, Heidelberg University Hospital, Heidelberg, Baden-Würrtemberg, Germany.
PLoS One. 2021 May 14;16(5):e0251829. doi: 10.1371/journal.pone.0251829. eCollection 2021.
The implantation of cardiac implantable electronic devices (CIED) has increased in the last decades with improvement in the quality of life of patients with cardiac rhythm disorders. The presence of bilateral subclavian, innominate or superior vena cava obstruction is a major limitation to device revision and/or upgrade.
This is retrospective study of patients who underwent laser-assisted lead extraction (LLE) (GlideLight laser sheath, Spectranetics Corporation, Colorado Springs, USA) with lead revision or upgrade using the laser sheath as a guide rail. Patients with known occlusion, severe stenosis or functional obstruction of the venous access vessels with indwelling leads were included in this study.
106 patients underwent percutaneous LLE with lead revision and/or upgrade. Preoperative known complete occlusion or severe stenosis of access veins was present in 23 patients (21.5%). More patients with implantable cardioverter-defibrillator (ICD) underwent LLE (64.1%) than patients with CRT-Ds (24.5%) and pacemaker patients (11.3%). In total 172 leads were extracted: 79 (45.9%) single-coil defibrillator leads, 35 (20.3%) dual-coil defibrillator leads, 31 (18.0%) right atrial leads, 24 (13.9%) right ventricular leads and three (1.7%) malfunctional coronary sinus left ventricular pacing leads. The mean age of leads was 99.2±65.6 months. The implantation of new leads after crossing the venous stenosis/obstruction was successful in 98 (92.4%) cases. Postoperative complications were pocket hematoma in two cases and wound infection in one case. No peri-operative and no immediate postoperative death was recorded. One intraoperative superior vena cava tear was treated by immediate thoracotomy and surgical repair.
In a single-center study on LLE in the presence of supra-cardiac occlusion of the central veins for CIED lead upgrade and revision we could demonstrate a low procedural complication rate with no procedural deaths. Most of the leads could be completely extracted to revise or upgrade the system. Our study showed a low complication rate, with acceptable mortality rates.
在过去几十年中,随着心律失常患者生活质量的提高,心脏植入式电子设备(CIED)的植入量有所增加。双侧锁骨下静脉、无名静脉或上腔静脉阻塞是设备翻修和/或升级的主要限制因素。
这是一项回顾性研究,纳入了在中心静脉至上腔静脉阻塞的情况下接受激光辅助导线拔除(LLE)(GlideLight 激光鞘,Spectranetics Corporation,科罗拉多斯普林斯,美国)的患者,这些患者使用激光鞘作为导轨进行导线翻修或升级。本研究纳入了已知静脉通路血管存在闭塞、严重狭窄或功能障碍且留置导线的患者。
106 例患者接受了经皮 LLE 导线翻修和/或升级。术前已知静脉通路完全闭塞或严重狭窄的患者有 23 例(21.5%)。接受 LLE 的患者中,植入式心脏复律除颤器(ICD)患者多于心脏再同步化治疗除颤器(CRT-D)患者(64.1% vs. 24.5%)和起搏器患者(11.3%)。共拔除 172 根导线:79 根(45.9%)单线圈除颤器导线、35 根(20.3%)双线圈除颤器导线、31 根(18.0%)右心房导线、24 根(13.9%)右心室导线和 3 根(1.7%)功能不良的冠状窦左心室起搏导线。导线的平均年龄为 99.2±65.6 个月。在穿过静脉狭窄/阻塞处植入新导线后,98 例(92.4%)患者获得成功。术后并发症包括 2 例囊袋血肿和 1 例伤口感染。无围手术期和即刻术后死亡病例。1 例术中上腔静脉撕裂患者立即行开胸手术和外科修复。
在单中心研究中,我们对 CIED 导线升级和翻修时中心静脉至上腔静脉阻塞的患者进行了 LLE,结果显示该手术具有较低的程序并发症发生率,且无程序相关死亡。大多数导线都可以完全拔除以进行翻修或升级系统。我们的研究显示出较低的并发症发生率和可接受的死亡率。